Uhrt eRNA Inhibits Myocardial Transcriptional Complex Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective methods to inhibit the formation of the transcriptional complex between myocardial enhancer DNA and the promoters of myosin heavy chain genes in cardiomyocytes, which is crucial for regulating cardiac function and preventing hypertrophy.
Innovation Solution
The use of noncoding myocardial enhancer RNAs (eRNAs), specifically the cardioprotective eRNA named Uheart (Uhrt), to inhibit the assembly of the enhancer DNA-Myh6 promoter-Myh7 promoter complex by enhancing the binding of Uhrt to the enhancer DNA, thereby modulating gene expression and cardiac function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enhancer-promoter interactions are increased to regulate gene expression, then gene regulation capability is improved, but formation of pathological transcriptional complexes increases
Solution Approach 1:
The patent introduces enhancer RNAs (eRNAs) as intermediary molecules that bind to enhancer DNA and prevent the formation of pathological transcriptional complexes. These eRNAs act as mediators between the enhancer and promoter regions, blocking aberrant interactions while allowing legitimate gene regulation to proceed, thus resolving the contradiction between gene regulation capability and pathological complex formation
Solution Approach 2:
The patent extracts and utilizes the enhancer RNA component from the enhancer-promoter interaction system. By separating the eRNA from the traditional DNA-only enhancer model and employing it as a therapeutic agent, the invention removes the harmful transcriptional complex formation while preserving beneficial gene regulation functions
2Reliability
If noncoding eRNAs are used to inhibit transcriptional complexes, then pathological hypertrophy is prevented, but device complexity increases
Solution Approach 1:
The patent employs endogenous enhancer RNAs that are naturally produced by the cell's own enhancer regions. Rather than introducing external therapeutic molecules, the system uses self-produced eRNAs to inhibit pathological transcriptional complexes, allowing the cell to self-regulate and preventing hypertrophy without requiring complex external intervention devices
Solution Approach 2:
The patent modifies the functional state of enhancer RNAs by changing their concentration or stability parameters to achieve therapeutic effects. By adjusting eRNA levels or half-life, the invention controls the inhibition of transcriptional complexes, providing a simplified parameter-based control mechanism rather than complex device intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Inhibiting the enhancer DNA-Myh6 promoter-Myh7 promoter complex with Uhrt eRNA effectively regulates myocardial gene expression, preventing pathological hypertrophy and maintaining cardiac homeostasis.
Implementation Method 1
enhancing the binding of Uhrt to the enhancer DNA
Data Source
AI summary
Disclosed are methods of detecting myocardial enhancer RNA levels in mammalian cardiomyocytes. In a further embodiment, a method of disrupting assembly of an enhancer DNA-Myh6 promoter-Myh7 promoter complex, is provided wherein the method comprises providing enhancer RNA to a cardiomyocyte.